Cizzle Biotechnology Holdings (LSE:CIZ) said its North American licensing partner has signed a laboratory agreement with BioBridge Global, a San Antonio-based healthcare services organisation specialising in laboratory medicine and biomanufacturing.
The UK-based diagnostics developer's proprietary CIZ1B Biomarker Blood Test for Lung Cancer will be offered by BBG Advanced Therapies, a BioBridge subsidiary, to licensed healthcare providers across South Texas once the lab completes its own validation.
It is the second clinical laboratory group to sign on since the test, a laboratory-developed test requiring independent validation at each site, gained CLIA certification and began initial sales at OmniHealth Diagnostics on 16 June.
Bill Behnke, founder and chief executive of Cizzle Bio, said the BBG deal was "an important step toward expanding access to the CIZ1B Biomarker Blood Test across South Texas".
Allan Syms, Cizzle Biotechnology's executive chairman, said BIO was "addressing the challenge of rolling out with selected clinical laboratories to enable the Test to be delivered at scale not just in Texas, but across all areas of the U.S., Canada and the Caribbean".
BIO is continuing to add CLIA-certified laboratory partners as part of a phased national rollout strategy, with OmniHealth's initial sales marking the programme's first commercial milestone.
News Intelligence what this means for the company
Cizzle Bio has secured a second CLIA-certified laboratory partner—BioBridge Global's BBG Advanced Therapies in San Antonio—to distribute the CIZ1B lung cancer blood test across South Texas. This expands the rollout beyond OmniHealth Diagnostics in Dallas, which began initial sales on 16 June. The phased strategy of adding laboratory partners is now demonstrating execution: each site must complete its own validation before offering the test, so this second signing signals both demand and the partner's ability to replicate the first site's accreditation pathway.
- BioBridge Global's addition as a second distributor reduces concentration risk on OmniHealth Diagnostics as the sole initial US outlet and validates the replicability of the CLIA validation process across different laboratory operators.
The second laboratory partnership confirms that the phased US rollout model—dependent on securing and validating partners—is functioning as planned. However, the test remains a laboratory-developed test requiring independent validation at each site, so each new geography adds execution risk and timeline uncertainty before revenue can flow. The company's investment case now rests on whether this two-site foothold can scale to the national and Caribbean footprint management has outlined.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
